Last reviewed · How we verify
Influenza Virus Quadrivalent Inactivated Vaccine
The Influenza Virus Quadrivalent Inactivated Vaccine, developed by the National Institute of Allergy and Infectious Diseases (NIAID), is currently marketed but lacks specific revenue data. A key strength is the protection it offers against four strains of the influenza virus, with a key composition patent expiring in 2028. The primary risk is the intense competition in the influenza vaccine market, where multiple established players offer similar quadrivalent vaccines.
At a glance
| Generic name | Influenza Virus Quadrivalent Inactivated Vaccine |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- BPL-1357 Against H1N1 Influenza Virus Challenge (PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients (PHASE2)
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults (PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults (PHASE1)
- Flublok or Fluzone With Advax-CpG55.2 or AF03 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: